Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Abstract Background In patients with rheumatic diseases, the use of biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) after discontinuation of tumor necrosis factor inhibitors (TNFi) is known to be effective. However, data on the use of TNFi after discontinuati...

Full description

Bibliographic Details
Main Authors: Manuel Pombo-Suárez, Daniel Seoane-Mato, Federico Díaz-González, Fernando Sánchez-Alonso, Marta Sánchez-Jareño, Luis Cea-Calvo, Isabel Castrejón
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Advances in Rheumatology
Subjects:
Axial spondyloarthritis
Golimumab
Medication retention
Psoriatic arthritis
Rheumatoid arthritis
Online Access:https://doi.org/10.1186/s42358-023-00296-1

Internet

https://doi.org/10.1186/s42358-023-00296-1

Similar Items